Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Co-promotion partner Takeda will focus sales activities on office-based gastroenterologists and primary care physicians, while Sucampo will target medical centers and the VA.
You may also be interested in...
Japan Clears Nine Drugs For Approval, But Only A New DPP-4 Is First Out The Gate
Despite MHLW's progress in cutting the drug lag, no drugs from a June 29 batch of approvals are first-to-market save for a DPP-4 from Mitsubishi Tanabe, which enters a crowded market.
Sucampo/Takeda’s Amitiza Gains IBS-C Indication
Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.
Sucampo/Takeda’s Amitiza Gains IBS-C Indication
Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.